Genetic Research in Schizophrenia
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 14, 2005 | ||||
Last Updated Date | November 17, 2011 | ||||
Start Date ICMJE | January 2004 | ||||
Estimated Primary Completion Date | December 2015 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Genetic Association [ Time Frame: ten years ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00108303 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE | |||||
Original Secondary Outcome Measures ICMJE | |||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Genetic Research in Schizophrenia | ||||
Official Title ICMJE | Genetic Research in Schizophrenia | ||||
Brief Summary | Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause childhood and adult onset schizophrenia. |
||||
Detailed Description | It is known from genetic linkage and gene expression studies that the alpha 7 nicotinic receptor gene is abnormally expressed in people with schizophrenia. The immediate objectives of this proposal support the long-term objectives of a comprehensive description of the pathophysiology of schizophrenia and new drug treatments by carefully defining the physiological genotype-phenotype relationship for a single candidate gene. Subjects and family members with a mental illness or who appear to have a mental illness will be asked to undergo an interview, perform some mental tests and have a blood, urine, and saliva sample taken one time. |
||||
Study Type ICMJE | Observational | ||||
Study Design ICMJE | Observational Model: Case Control Time Perspective: Prospective |
||||
Biospecimen | Retention: Samples With DNA Description: dna |
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | Persons with schizophrenia |
||||
Condition ICMJE | Schizophrenia | ||||
Intervention ICMJE | |||||
Study Group/Cohort (s) | 1 | ||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE | 3000 | ||||
Estimated Completion Date | December 2020 | ||||
Estimated Primary Completion Date | December 2015 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 1 Year and older | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts ICMJE |
|
||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00108303 | ||||
Other Study ID Numbers ICMJE | ADRD-007-03S | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Department of Veterans Affairs | ||||
Study Sponsor ICMJE | Department of Veterans Affairs | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Department of Veterans Affairs | ||||
Verification Date | November 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |